<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 25 May 2021 07:30:12 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>FGF19类似物2b期临床失败，NGM股价腰斩</title><link>https://mp.weixin.qq.com/s/lkV_tsj9H7T-HMAa5U0RRA</link><description></description><content:encoded><![CDATA[FGF19类似物2b期临床失败，NGM股价腰斩]]></content:encoded><pubDate>Tue, 25 May 2021 06:04:05 +0800</pubDate></item><item><title>微小RNA疗法脱颖而出：ABX464治疗溃疡性结肠炎2b期临床成功</title><link>https://mp.weixin.qq.com/s/YXHwkL14Y8TvnpLPiIu52g</link><description></description><content:encoded><![CDATA[微小RNA疗法脱颖而出：ABX464治疗溃疡性结肠炎2b期临床成功]]></content:encoded><pubDate>Tue, 25 May 2021 06:04:05 +0800</pubDate></item><item><title>多发性骨髓瘤新靶点：强生GPRC5D/CD3双抗早期临床数据优异</title><link>https://mp.weixin.qq.com/s/7a6JPnekxOI12h0cGcuISg</link><description></description><content:encoded><![CDATA[多发性骨髓瘤新靶点：强生GPRC5D/CD3双抗早期临床数据优异]]></content:encoded><pubDate>Tue, 25 May 2021 06:04:05 +0800</pubDate></item><item><title>首个ADC类似药印度上市，价格降低80%</title><link>https://mp.weixin.qq.com/s/FgDxEG6tAZMkknpYFgKiuw</link><description></description><content:encoded><![CDATA[首个ADC类似药印度上市，价格降低80%]]></content:encoded><pubDate>Tue, 25 May 2021 06:04:05 +0800</pubDate></item><item><title>武田TAK-788中国申报上市，拟优先审评</title><link>https://mp.weixin.qq.com/s/enxZpB8q_4iuervamPvTYw</link><description></description><content:encoded><![CDATA[武田TAK-788中国申报上市，拟优先审评]]></content:encoded><pubDate>Tue, 25 May 2021 06:04:05 +0800</pubDate></item><item><title>康方生物PD-1递交美国上市申请：入选RTOR，比优先审评更快</title><link>https://mp.weixin.qq.com/s/C9ozYU78Ty9MFvwlrXnL2w</link><description></description><content:encoded><![CDATA[康方生物PD-1递交美国上市申请：入选RTOR，比优先审评更快]]></content:encoded><pubDate>Mon, 24 May 2021 08:54:37 +0800</pubDate></item><item><title>FDA批准第3款双抗：强生EGFR/cMET</title><link>https://mp.weixin.qq.com/s/rnuKGyx9BtRxpvPcHeMLNA</link><description></description><content:encoded><![CDATA[FDA批准第3款双抗：强生EGFR/cMET]]></content:encoded><pubDate>Sat, 22 May 2021 07:13:38 +0800</pubDate></item><item><title>HER2：新时代的研发竞争</title><link>https://mp.weixin.qq.com/s/pKmyzfo4ASi22olDNudMBg</link><description></description><content:encoded><![CDATA[HER2：新时代的研发竞争]]></content:encoded><pubDate>Fri, 21 May 2021 13:23:06 +0800</pubDate></item><item><title>激酶抑制剂二十年</title><link>https://mp.weixin.qq.com/s/VkZnyowv0dlQQHw84iXQUg</link><description></description><content:encoded><![CDATA[激酶抑制剂二十年]]></content:encoded><pubDate>Fri, 21 May 2021 13:23:06 +0800</pubDate></item><item><title>RAS靶向治疗研发格局</title><link>https://mp.weixin.qq.com/s/ecLcEwhDB7nt34aSj_Hzwg</link><description></description><content:encoded><![CDATA[RAS靶向治疗研发格局]]></content:encoded><pubDate>Fri, 21 May 2021 13:23:06 +0800</pubDate></item><item><title>CRS：细胞因子风暴</title><link>https://mp.weixin.qq.com/s/aWsN3EQ5-Gr1g1zs1z2KzA</link><description></description><content:encoded><![CDATA[CRS：细胞因子风暴]]></content:encoded><pubDate>Fri, 21 May 2021 13:23:06 +0800</pubDate></item><item><title>恒瑞医药三天申报2款大分子新药</title><link>https://mp.weixin.qq.com/s/7GD4yIluwAnhTwuIn53mfA</link><description></description><content:encoded><![CDATA[恒瑞医药三天申报2款大分子新药]]></content:encoded><pubDate>Fri, 21 May 2021 13:23:06 +0800</pubDate></item><item><title>TGFβ或αvβ8：辉瑞如何选择？</title><link>https://mp.weixin.qq.com/s/DvS77AmDnuiz-RHSeBSsVw</link><description></description><content:encoded><![CDATA[TGFβ或αvβ8：辉瑞如何选择？]]></content:encoded><pubDate>Thu, 20 May 2021 08:23:05 +0800</pubDate></item><item><title>映恩生物完成9000万美元B轮融资</title><link>https://mp.weixin.qq.com/s/OFb30OhSS0FMSwVAmenwiw</link><description></description><content:encoded><![CDATA[映恩生物完成9000万美元B轮融资]]></content:encoded><pubDate>Thu, 20 May 2021 08:23:05 +0800</pubDate></item><item><title>百时美施贵宝15.6亿美元引进的TIGIT双抗是什么</title><link>https://mp.weixin.qq.com/s/EOVcJccTVe4oD5Sob1HMtg</link><description></description><content:encoded><![CDATA[百时美施贵宝15.6亿美元引进的TIGIT双抗是什么]]></content:encoded><pubDate>Wed, 19 May 2021 06:59:21 +0800</pubDate></item><item><title>结构生物学最新技术| MicroED能为共晶结构解析带来什么？</title><link>https://mp.weixin.qq.com/s/jSBnw_aW5ZPJYboN8xYapw</link><description></description><content:encoded><![CDATA[结构生物学最新技术| MicroED能为共晶结构解析带来什么？]]></content:encoded><pubDate>Wed, 19 May 2021 06:59:21 +0800</pubDate></item><item><title>信达生物PD-1美国上市申请获受理</title><link>https://mp.weixin.qq.com/s/cUaAslMF2tbvDeha4YFL0Q</link><description></description><content:encoded><![CDATA[信达生物PD-1美国上市申请获受理]]></content:encoded><pubDate>Tue, 18 May 2021 12:57:02 +0800</pubDate></item><item><title>ProTriTAC技术</title><link>https://mp.weixin.qq.com/s/dVJBn1gORZCcoayiSKc-9Q</link><description></description><content:encoded><![CDATA[ProTriTAC技术]]></content:encoded><pubDate>Tue, 18 May 2021 12:57:02 +0800</pubDate></item><item><title>TRuC-T细胞疗法，配备PD-1/CD28开关</title><link>https://mp.weixin.qq.com/s/6gjwzjVnu8u5sR6h031G0Q</link><description></description><content:encoded><![CDATA[TRuC-T细胞疗法，配备PD-1/CD28开关]]></content:encoded><pubDate>Tue, 18 May 2021 12:57:02 +0800</pubDate></item><item><title>PD-1/HER2：信达生物、三生国健、上海药物所</title><link>https://mp.weixin.qq.com/s/V2jBWgZzCF41hpoupC7Z3g</link><description></description><content:encoded><![CDATA[PD-1/HER2：信达生物、三生国健、上海药物所]]></content:encoded><pubDate>Tue, 18 May 2021 12:57:02 +0800</pubDate></item></channel></rss>